資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/120757
|
題名: | Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan |
作者: | Chen, Yi-Wei;Lee, Yi-Yen;Lin, Chun-Fu;Pan, Po-Shen;Chen, Jen-Kun;Wang, Chun-Wei;Hsu, Shih-Ming;Kuo, Yu-Cheng;Lan, Tien-Li;Hsu, Sanford P. C.;Liang, Muh-Lii;Chen, Robert Hsin-Hung;Chang, Feng-Chi;Wu, Chih-Chun;Lin, Shih-Chieh;Liang, Hsiang-Kuang;Lee, Jia-Cheng;Chen, Shih-Kuan;Liu, Hong-Ming;Peir, Jinn-Jer;Lin, Ko-Han;Huang, Wen-Sheng;Chen, Kuan-Hsuan;Kang, Yu-Mei;Liou, Shueh-Chun;Wang, Chun-Chieh;Pai, Ping-Ching;Li, Chih-Wei;Chiek, Daniel Quah Song;Wong, Tai-Tong;Chiou, Shih-Hwa;Chao, Yee;Tanaka, Hiroki;Chou, Fong-In;Ono, Koji |
關鍵詞: | BNCT;glioblastoma;T/N ratio;T/B ratio;radioresistance |
日期: | 2021-04-15 |
上傳時間: | 2021-05-06 12:11:12 (UTC+8) |
出版者: | MDPI |
摘要: | Although boron neutron capture therapy (BNCT) is a promising treatment option for malignant brain tumors, the optimal BNCT parameters for patients with immediately life-threatening, end-stage brain tumors remain unclear. We performed BNCT on 34 patients with life-threatening, end-stage brain tumors and analyzed the relationship between survival outcomes and BNCT parameters. Before BNCT, MRI and 18F-BPA-PET analyses were conducted to identify the tumor location/distribution and the tumor-to-normal tissue uptake ratio (T/N ratio) of 18F-BPA. No severe adverse events were observed (grade ≥ 3). The objective response rate and disease control rate were 50.0% and 85.3%, respectively. The mean overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) times were 7.25, 7.80, and 4.18 months, respectively. Remarkably, the mean OS, CSS, and RFS of patients who achieved a complete response were 17.66, 22.5, and 7.50 months, respectively. Kaplan–Meier analysis identified the optimal BNCT parameters and tumor characteristics of these patients, including a T/N ratio ≥ 4, tumor volume < 20 mL, mean tumor dose ≥ 25 Gy-E, MIB-1 ≤ 40, and a lower recursive partitioning analysis (RPA) class. In conclusion, for malignant brain tumor patients who have exhausted all available treatment options and who are in an immediately life-threatening condition, BNCT may be considered as a therapeutic approach to prolong survival. |
關聯: | Biology 10(4), 334 |
DOI: | 10.3390/biology10040334 |
顯示於類別: | [化學學系暨研究所] 期刊論文
|
文件中的檔案:
檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
index.html | | 0Kb | HTML | 137 | 檢視/開啟 |
|
在機構典藏中所有的資料項目都受到原著作權保護.
|